search button

Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications

  • Authors:
    • Xingxiang Pu
    • Zhizhong Pan
    • Ying Huang
    • Ying Tian
    • Hongqiang Guo
    • Lin Wu
    • Xuexing He
    • Xinggui Chen
    • Shaodan Zhang
    • Tongyu Lin

  • View Affiliations

  • Published online on: October 10, 2012     https://doi.org/10.3892/ol.2012.963
  • Pages: 249-254
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In colorectal cancer (CRC), KRAS and BRAF mutations in primary tumors are associated with resistance to anti-epidermal growth factor receptor (anti‑EGFR)-based therapies. However, the correlation between KRAS/BRAF mutation in primary tumors and serum has not been well studied. To evaluate the degree of concordance of KRAS/BRAF mutations between the primary tumors and the matched serum samples in CRC, serum and tumor tissues were collected from 115 patients with CRC and KRAS/BRAF mutations were examined by nested polymerase chain reaction (PCR) and direct sequencing. BRAF mutations were present in 3.5% (4/115) of the primary tumor tissue samples and 0.87% (1/115) of the serum samples. In the 4 primary tumors with BRAF mutations, identical mutations were not observed in the corresponding serum samples (κ=-0.016). KRAS mutations were observed in 32.2% (37/115) of the primary tumors and 11.3% (13/115) of the serum samples. Of the 37 tumor cases with KRAS mutations, 9 had identical mutations in the corresponding serum sample, with a concordance rate of 24.3% (9/37). Discordance was observed in 32 (27.8%) patients. The concordance between KRAS mutations in the primary tumors and KRAS mutations in the matched serums was low (κ=0.231). The results of the present study suggest that the possibility of differences in the mutational status of KRAS/BRAF between primary tumors and matched serum samples should be considered when patients are selected for anti-EGFR-based therapies.
View References

Related Articles

Journal Cover

January 2013
Volume 5 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Pu X, Pan Z, Huang Y, Tian Y, Guo H, Wu L, He X, Chen X, Zhang S, Lin T, Lin T, et al: Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications. Oncol Lett 5: 249-254, 2013
APA
Pu, X., Pan, Z., Huang, Y., Tian, Y., Guo, H., Wu, L. ... Lin, T. (2013). Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications. Oncology Letters, 5, 249-254. https://doi.org/10.3892/ol.2012.963
MLA
Pu, X., Pan, Z., Huang, Y., Tian, Y., Guo, H., Wu, L., He, X., Chen, X., Zhang, S., Lin, T."Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications". Oncology Letters 5.1 (2013): 249-254.
Chicago
Pu, X., Pan, Z., Huang, Y., Tian, Y., Guo, H., Wu, L., He, X., Chen, X., Zhang, S., Lin, T."Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications". Oncology Letters 5, no. 1 (2013): 249-254. https://doi.org/10.3892/ol.2012.963